

Department of Radiation Oncology

Monthly Research Update: January 2023

NIH Data Sharing Reqs Now in Effect

JANUARY AT A GLANCE TOTALS

Clinical trials	
Total enrolled	31
GCC, other	5
NRG, NCI, co-ops	2
PCG Registry	24
Grants and contracts	
New awards	3
Submitted	2
Articles published	
	8

As of January 25, all applicants for National Institutes of Health (NIH) funding are required to comply with a new [Data Management and Sharing Policy](#) (DMS policy). Any applicant planning to generate scientific data and accompanying metadata must prepare a DMS plan that describes how these data will be managed and shared. To clarify these requirements, NIH has published a [list of activity codes](#) subject to DMS policy requirements. The UMSOM [Center for Advanced Research Training and Innovation](#) has hosted a series of information sessions on integrating the policy into new applications, including a [presentation](#) and links to [additional resources](#). A free, [web-based service](#) (DMPTool) is available to provide a stepwise process for developing a plan based on specific research, and the UMB Center for Data & Bioinformation Services is offering [consultations](#) to assist in creating a data management plan or in using the DMPTool.

The new policy “establishes the expectation that data sharing is a fundamental component of the research process and maximizes the public’s access to research results that arise from NIH-funded research,” said Lawrence A. Tabak, DDS, PhD, on January 15 on behalf of NIH. “NIH encourages the research community to embrace DMS plans as a new normal of research grant planning and administration.”

[Additional information and FAQs](#) have been posted by NIH. Note that implementation of this policy requires a detailed and specific plan that is likely to add time and effort in the application preparation process, as well as tasks that must be completed throughout the proposed funding period and incorporated into any associated timelines and personnel planning.

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu

Clinical Trial Enrollment

- 24 patients were enrolled at MPTC on the **PCG Registry**
- 1 patient was enrolled at MPTC on **GCC 20110**: A single-arm, single-stage phase II trial of selective avoidance of nodal volumes at minimal Risk (SAVER) in the contralateral neck of patients with p16-positive oropharynx cancer
- 1 patient was enrolled at UMMC on **NRG BN005**: A phase II randomized trial of proton vs. photon therapy (IMRT) for cognitive preservation in patients with IDH mutant, low to intermediate grade gliomas
- 1 patient was enrolled at BWMC on **Alliance A221803**: Mepitel film for the reduction of radiation dermatitis in breast cancer patients undergoing post-mastectomy radiation therapy: A randomized phase III clinical trial
- 1 patient was enrolled at BWMC on **GCC 15100**: Pragmatic phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial
- 1 patient was enrolled at MPTC on **GCC 19140**: Pilot study of laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of recurrent gliomas
- 1 patient was enrolled at MPTC on **GCC 19146**: Comparison and verification of radiation planning for pencil beam scanning proton therapy using single energy and dual energy computed tomography simulation methods
- 1 patient was enrolled at MPTC on **GCC 21136**: Phase II randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPS) trial

Grants and Contracts

Funded:

- **Erika Davies, PhD**, PI, from Xequel Bio, Master Service Research Agreement for “Assessing the efficacy of Granexin gel treatment following cutaneous radiation injury in the Yorkshire pig”. (2/2023–2/2028). Task order 1: “Pre-study: Begin hiring process for key personnel to perform on anticipated studies” (1/2023-6/2023) (\$384,145).
- **Hem Shukla, PhD**, PI, from the American Cancer Society for an Institutional Research Grant for “Human pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response and resistance to therapy” (1/2023–12/2023) (\$40,000).

Submitted:

- **Erika Davies, PhD**, PI, to PureTech LYT 100, Inc., for “30-day survival efficacy study to determine the effect of LYT-100 following post-irradiation, oral administration on 30-day mortality in the C57BL/6J model of acute radiation injury in the presence or absence of Neulasta treatment” (dates TBD) (\$301,641).
- **Erika Davies, PhD**, PI, to PureTech LYT 100, Inc., “30-day hematology parameter efficacy study to determine the effect of LYT-100 following post-irradiation, oral administration on recovery from neutropenia, thrombocytopenia and anemia in the C57BL/6J model of acute radiation injury in the presence or absence of Neulasta treatment” (dates TBD). (\$637,241).

Articles Published

Entered into PubMed January 12–February 9. Titles link to PubMed abstracts, with full-text links.

1. Hahn NM, O'Donnell MA, Efsthathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, **Tran PT**, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. [A phase 1 trial of durvalumab in combination with bacillus calmette-guerin \(BCG\) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.](#) *Eur Urol.* 2023 Jan 28:S0302-2838(23)00025-8. Online ahead of print.
2. Iqbal GMD, Zhang H, **D'Souza W**, Ha L, Rosenberger JM. [Four-dimensional computed tomography-based ventilation imaging in intensity-modulated radiation therapy treatment planning for pulmonary functional avoidance.](#) *J Appl Clin Med Phys.* 2023 Feb 2:e13920. Online ahead of print.
3. Merfeld EC, Witek ME, Francis DM, Burr AR, Wallace CR, Kuczmarska-Haas A, **Lamichhane N**, Kimple RJ, Glazer TA, Wieland AM, McCulloch TM, Hartig GK, Harari PM. [Interstitial brachytherapy for lip cancer: Technical aspects to individualize treatment approach and optimize outcomes.](#) *Pract Radiat Oncol.* 2023 Jan 25:S1879-8500(23)00006-1. Online ahead of print.
4. Parsons D, Joo M, Iqbal Z, Godley A, Kim N, Spangler A, Albuquerque K, **Sawant A**, Zhao B, Gu X, Rahimi A. [Stability and reproducibility comparisons between deep inspiration breath-hold techniques for left-sided breast cancer patients: A prospective study.](#) *J Appl Clin Med Phys.* 2023 Jan 23:e13906. Online ahead of print.
5. **Savla B**, **Hamza MA**, Yacubovich D, Cobbs S, Petrovska L, Scilla KA, Burrows W, Mehra R, Miller RC, Rolfo C, **Bentzen SM**, Mohindra P, **Vyfhuis MAL**. [The impact of body mass index \(BMI\) and residence in food priority areas \(FPAs\) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer.](#) *Int J Radiat Oncol Biol Phys.* 2023 Jan 28:S0360-3016(23)00080-9. Online ahead of print.
6. **Shukla HD**, **Dukic T**, **Roy S**, **Bhandary B**, Gerry A, **Poirier Y**, **Lamichhane N**, **Molitoris J**, **Carrier F**, Banerjee A, **Regine WF**, **Polf JC**. [Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response.](#) *Front Oncol.* 2023 Jan 12;12:1072774.
7. Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, **Mishra M**, **Rana Z**, **Molitoris J**, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, **Tran PT**. [WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer.](#) *Int J Radiat Oncol Biol Phys.* 2023 Jan 25:S0360-3016(22)03628-8. Online ahead of print.
8. Wang X, Raman N, Lemtiri-Chlieh G, **Chang J**, **Jagtap S**, Chowdhury DD, Ballew M, Carrieri FA, Nguyen T, Nugent K, Peck T, Levine MS, Chan A, Lam C, Malek R, Hoang T, Phillips R, Cheng Z, Taparra K, Connis N, Hann CL, Holland A, **Tran PT**, **Lafargue A**, Wang H. [Griseofulvin radiosensitizes non-small cell lung cancer cells and activates cGAS.](#) *Mol Cancer Ther.* 2023 Feb 7:MCT-22-0191. Online ahead of print.

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01 Resub. 03/05/23	02/21/23	02/23/23	02/27/23
R21 Resub. 03/16/23	03/03/23	03/07/23	03/09/23